These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 16945078

  • 21. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B, MANIF 2000 Study Group.
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [Abstract] [Full Text] [Related]

  • 22. Changes in nutritional, functional and immunological status of HIV-infected adults with antiretroviral therapy.
    Tafese Z, Berhan Y, Abebe H.
    Ethiop Med J; 2012 Jan; 50(1):75-87. PubMed ID: 22519164
    [Abstract] [Full Text] [Related]

  • 23. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 24. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X.
    AIDS; 2007 Nov 30; 21(18):2483-91. PubMed ID: 18025885
    [Abstract] [Full Text] [Related]

  • 25. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D, Berenguer J, Bellón JM, Miralles P, Cosin J, de Quiros JC, Conde MS, Muñoz-Fernández MA, Resino S.
    J Infect; 2008 Feb 30; 56(2):130-6. PubMed ID: 18192020
    [Abstract] [Full Text] [Related]

  • 26. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN.
    Clin Infect Dis; 2008 Jun 01; 46(11):1702-9. PubMed ID: 18419422
    [Abstract] [Full Text] [Related]

  • 27. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
    Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, Mercey D, Machala L, Horban A, Lundgren JD, EuroSIDA study group.
    J Infect Dis; 2004 Jul 01; 190(1):148-55. PubMed ID: 15195254
    [Abstract] [Full Text] [Related]

  • 28. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.
    AIDS; 2008 Sep 12; 22(14):1815-20. PubMed ID: 18753864
    [Abstract] [Full Text] [Related]

  • 29. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.
    AIDS; 2007 May 11; 21(8):939-46. PubMed ID: 17457087
    [Abstract] [Full Text] [Related]

  • 30. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.
    Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A.
    Int J Epidemiol; 2005 Jun 11; 34(3):577-84. PubMed ID: 15737969
    [Abstract] [Full Text] [Related]

  • 31. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.
    AIDS; 2006 Oct 03; 20(15):1941-50. PubMed ID: 16988515
    [Abstract] [Full Text] [Related]

  • 33. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.
    Clin Infect Dis; 2007 Jan 15; 44(2):295-300. PubMed ID: 17173234
    [Abstract] [Full Text] [Related]

  • 34. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G, Italian MASTER Cohort.
    J Antimicrob Chemother; 2007 Jun 15; 59(6):1141-7. PubMed ID: 17434879
    [Abstract] [Full Text] [Related]

  • 35. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 15; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 36. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group.
    HIV Med; 2007 Mar 15; 8(2):96-104. PubMed ID: 17352766
    [Abstract] [Full Text] [Related]

  • 37. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
    Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de la Tribonnière X, Viget N, Ajana F, Goffard A, Barin F, Mouton Y, Yazdanpanah Y.
    Antivir Ther; 2005 Mar 15; 10(2):247-54. PubMed ID: 15865219
    [Abstract] [Full Text] [Related]

  • 38. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 39. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi.
    Bong CN, Yu JK, Chiang HC, Huang WL, Hsieh TC, Schouten EJ, Makombe SD, Kamoto K, Harries AD.
    AIDS; 2007 Aug 20; 21(13):1805-10. PubMed ID: 17690580
    [Abstract] [Full Text] [Related]

  • 40. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
    Breton G, Lewden C, Spire B, Salmon D, Brun-Vézinet F, Duong M, Allavena C, Leport C, Salamon R, APROCO COPILOTE ANRS CO8 Study Group.
    HIV Med; 2007 Apr 20; 8(3):164-70. PubMed ID: 17461860
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.